This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy.
CONFIRM

ABOUT ACEPODIA

Powerful, Off-the-Shelf Cell Therapies Made Accessible

We are transforming cancer treatment with first-in-class cell therapies, with enhanced and targeted potency, improved safety and broad applicability across hematologic and solid tumor cancers. Our lead NK cell therapies are designed to offer countless patients a powerful anti-cancer therapeutic option.

TECHNOLOGY

  • Supercharged Cell Therapies
  • oNK Cells
  • ACC
  • CAR
  • γδ T Cells
  • Supercharged Cell Therapies
    TECHNOLOGY

    Supercharged Cell Therapies

    Uniting Specialized Cancer Killing Immune Cells with Tumor Targeting Technologies

    Acepodia’s first-in-class cell therapies consist of proprietary immune cell lines with enhanced cytotoxic properties that are supercharged with cancer targeting technologies to maximize anti-cancer activity directly against tumors. The company’s lead product candidate is ACE1702, an off-the-shelf antibody-conjugated natural killer cell therapy in clinical development for the treatment of HER2-expressing solid tumors.

  • oNK Cells
    TECHNOLOGY

    oNK Cells

    Amplified Natural Killer Cells for Off-the-Shelf Cancer-Killing Potential

    oNK cells are a proprietary natural killer (NK) cell line that is derived from the 1-2% of NK cells that have enhanced cytotoxic properties through their over expression of activation receptors and very low expression of inhibitory receptors. oNK cells can be augmented using established and novel technologies to target and engage solid tumors and hematological malignancies.

  • ACC
    TECHNOLOGY

    ACC

    Linking Tumor-Targeting Antibodies

    Acepodia’s proprietary antibody cell-conjugation platform (ACC) uses live-cell compatible chemistry to attach tumor-targeting antibodies directly to the surface of immune cells to generate highly specific and potent cell therapies, without the need for genetic engineering. The ACC platform can significantly enhance the potency of immune cells, thereby addressing the current challenge of treating solid tumors with cellular therapy. Acepodia is utilizing its ACC technology with its oNK cells and gamma delta T cells.

  • CAR
    TECHNOLOGY

    CAR

    Equipping Potent Cells with Validated Tumor Targeting

    Chimeric antigen receptor (CAR) technology is a well-established approach to augment immune cells to fight cancer. CAR’s are designed to be specific for tumor antigens and can be genetically introduced into immune cells, such as NK cells or T cells, to allow them to recognize and engage cancer cells. Acepodia is applying this technology to its oNK cells and gamma delta T cells.

  • γδ T Cells
    TECHNOLOGY

    γδ T Cells

    Eliciting a Robust Anticancer Immune Response

    Gamma delta (γδ) T cells have a unique T-cell receptor on their surface enabling them to participate in both adaptive and innate immune responses, but they represent only a small subset of T cells in peripheral blood. In addition to being inherently cytotoxic towards tumors, gamma delta T cells can recruit other immune cells to elicit a robust anti-cancer immune response. Acepodia is developing allogeneic gamma delta T cells for use in its cell therapy programs.

PIPELINE

PROMISING PIPELINE OF CELL THERAPIES

ACC

Program
Discovery
Preclinical
Phase I
Phase II
ACE1702
HER2 Targeting, ACC-oNK Cell Therapy
Phase I ​
ACE1975
CD70 Targeting, ACC-oNK Cell Therapy
Preclinical ​
ACE1831
CD20 Targeting, ACC-γδ T Cell Therapy
Preclinical ​
ACE1708
PD-L1 Targeting, ACC-oNK Cell Therapy
Preclinical ​

CAR

Program
Discovery
Preclinical
Phase I
Phase II
ACE1755 (Safety+)
CD19 Targeting, CAR-oNK Cell Therapy
Preclinical ​

LATEST NEWS

ADVANCING THE NEXT GENERATION OF IMMUNOTHERAPY

Highlight Publication Series on LinkedIn Page
CURRENT EVENT

Highlight Publication Series on LinkedIn Page

We just launched our next highlight publication series on LinkedIn. This series will focus on NK cell receptors. Follow us to learn more.
7th China Healthcare Summit
CURRENT EVENT

7th China Healthcare Summit

Acepodia is going to present a corporate overview at the upcoming 7th China Healthcare Summit on November 9, 2020.
ALL_layout_20H24_mjfmd535kv Presenter: Dr. Sonny Hsiao, CEO of Acepodia
ALL_layout_20H24_h73728pbpc Date: November 9, 2020
ALL_layout_20H24_ax38gurb7t Location: Virtual
35th Society for Immunotherapy of Cancer
CURRENT EVENT

35th Society for Immunotherapy of Cancer

Acepodia is going to present a late-breaking poster that indicates our lead clinical candidate's potential to combat solid tumors at SITC.
ALL_layout_20H24_mjfmd535kv Presenter: Dr. Howard Li, Preclinical Research Scientist
ALL_layout_20H24_h73728pbpc Date: November 9-14, 2020
ALL_layout_20H24_ax38gurb7t Location: Virtual
Biomanufacturing World Summit
UPCOMING EVENT

Biomanufacturing World Summit

Our Chairman and Co-Founder, Dr. Patrick Yang, will Co-Chair the Biomanufacturing World Summit hosted by Executive Platforms.
ALL_layout_20H24_mjfmd535kv Presenter: Dr. Patrick Yang, Co-Founder and Chairman of Acepodia
ALL_layout_20H24_h73728pbpc Date: November 16-17, 2020
ALL_layout_20H24_ax38gurb7t Location: Virtual